These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 30097434)
1. A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. Lee V; Wang J; Zahurak M; Gootjes E; Verheul HM; Parkinson R; Kerner Z; Sharma A; Rosner G; De Jesus-Acosta A; Laheru D; Le DT; Oganesian A; Lilly E; Brown T; Jones P; Baylin S; Ahuja N; Azad N Clin Cancer Res; 2018 Dec; 24(24):6160-6167. PubMed ID: 30097434 [TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954 [TBL] [Abstract][Full Text] [Related]
3. A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. Matei D; Ghamande S; Roman L; Alvarez Secord A; Nemunaitis J; Markham MJ; Nephew KP; Jueliger S; Oganesian A; Naim S; Su XY; Keer H; Azab M; Fleming GF Clin Cancer Res; 2018 May; 24(10):2285-2293. PubMed ID: 29500276 [No Abstract] [Full Text] [Related]
4. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. Papadatos-Pastos D; Yuan W; Pal A; Crespo M; Ferreira A; Gurel B; Prout T; Ameratunga M; Chénard-Poirier M; Curcean A; Bertan C; Baker C; Miranda S; Masrour N; Chen W; Pereira R; Figueiredo I; Morilla R; Jenkins B; Zachariou A; Riisnaes R; Parmar M; Turner A; Carreira S; Yap C; Brown R; Tunariu N; Banerji U; Lopez J; de Bono J; Minchom A J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35717027 [TBL] [Abstract][Full Text] [Related]
5. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients. Lee V; Parkinson R; Zahurak M; Cope L; Cercek A; Verheul H; Gootjes E; Lenz HJ; Iqbal S; Jones P; Baylin S; Rami V; Ahuja N; El Khoueiry A; Azad NS Int J Cancer; 2024 May; 154(10):1794-1801. PubMed ID: 38312102 [TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). Crabb SJ; Danson S; Catto JWF; Hussain S; Chan D; Dunkley D; Downs N; Marwood E; Day L; Saunders G; Light M; Whitehead A; Ellis D; Sarwar N; Enting D; Birtle A; Johnson B; Huddart R; Griffiths G Clin Cancer Res; 2021 Apr; 27(7):1882-1892. PubMed ID: 33472913 [TBL] [Abstract][Full Text] [Related]
7. Retreatment of Irinotecan in Later Lines of Therapy for Metastatic Colorectal Cancer: A Retrospective Study. Choi MK; Cha Y; Baek JY Oncology; 2021; 99(10):665-672. PubMed ID: 34515197 [TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Garrido-Laguna I; McGregor KA; Wade M; Weis J; Gilcrease W; Burr L; Soldi R; Jakubowski L; Davidson C; Morrell G; Olpin JD; Boucher K; Jones D; Sharma S Invest New Drugs; 2013 Oct; 31(5):1257-64. PubMed ID: 23504398 [TBL] [Abstract][Full Text] [Related]
10. Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in Townsend A; Tebbutt N; Karapetis C; Cooper P; Singhal N; Yeend S; Pirc L; Joshi R; Hardingham J; Price T Clin Cancer Res; 2018 Aug; 24(16):3838-3844. PubMed ID: 29739790 [No Abstract] [Full Text] [Related]
11. Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. Di Giacomo AM; Covre A; Finotello F; Rieder D; Danielli R; Sigalotti L; Giannarelli D; Petitprez F; Lacroix L; Valente M; Cutaia O; Fazio C; Amato G; Lazzeri A; Monterisi S; Miracco C; Coral S; Anichini A; Bock C; Nemc A; Oganesian A; Lowder J; Azab M; Fridman WH; Sautès-Fridman C; Trajanoski Z; Maio M Clin Cancer Res; 2019 Dec; 25(24):7351-7362. PubMed ID: 31530631 [TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer. Albany C; Fazal Z; Singh R; Bikorimana E; Adra N; Hanna NH; Einhorn LH; Perkins SM; Sandusky GE; Christensen BC; Keer H; Fang F; Nephew KP; Spinella MJ Cancer Med; 2021 Jan; 10(1):156-163. PubMed ID: 33135391 [TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of S-1 and irinotecan (IRIS) combined with cetuximab in patients with RAS wild-type metastatic colorectal cancer (KSCC1401). Samura H; Oki E; Okumura H; Yoshida T; Kai S; Kobayashi K; Kinjo T; Mori S; Tohyama T; Ohgaki K; Kawanaka H; Makiyama A; Ureshino N; Kotaka M; Shimose T; Ando K; Saeki H; Baba H; Maehara Y; Mori M Cancer Chemother Pharmacol; 2020 Aug; 86(2):285-294. PubMed ID: 32734398 [TBL] [Abstract][Full Text] [Related]
14. Modified-irinotecan/fluorouracil/levoleucovorin therapy as ambulatory treatment for metastatic colorectal cancer: results of phase I and II studies. Yuuki S; Komatsu Y; Fuse N; Kato T; Miyagishima T; Kudo M; Watanabe M; Tateyama M; Kunieda Y; Wakahama O; Sakata Y; Asaka M Clin Drug Investig; 2010; 30(4):243-9. PubMed ID: 20225907 [TBL] [Abstract][Full Text] [Related]
15. Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer. Saunders MP; Hogg M; Carrington B; Sjursen AM; Allen J; Beech J; Swindell R; Valle JW Br J Cancer; 2004 Oct; 91(8):1447-52. PubMed ID: 15452550 [TBL] [Abstract][Full Text] [Related]
16. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968 [TBL] [Abstract][Full Text] [Related]
17. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. Folprecht G; Hamann S; Schütte K; Trarbach T; Stoehlmacher-Williams J; Ehninger G BMC Cancer; 2014 Jul; 14():521. PubMed ID: 25038824 [TBL] [Abstract][Full Text] [Related]
18. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial. Ma CJ; Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Chang YT; Wang JY Trials; 2019 Dec; 20(1):751. PubMed ID: 31856912 [TBL] [Abstract][Full Text] [Related]
19. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105 [TBL] [Abstract][Full Text] [Related]
20. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer. Ma CJ; Huang CW; Yeh YS; Tsai HL; Hu HM; Wu IC; Cheng TL; Wang JY Oncol Res; 2017 May; 25(5):673-679. PubMed ID: 27938508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]